Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 May 2004

Safety and tolerability of the combination therapy with pegylatedinterferon alfa-2a (Pegasys®) and ribavirin (Copegus®) in patientswith chronic hepatitis C in Poland – interim analysis of data fromEAP program

Marta Wawrzynowicz-Syczewska, Marek Wasilewski, Hanna Trocha, Ewa Topczewska-Staubach, Krzysztof Tomasiewicz, Katarzyna Świętek, Katarzyna Szamotulska, Katarzyna Sikorska, Andrzej Horban, Marek Beniowski, Hanna Berak, Beata Bolewska, Anna Boroń-Kaczmarska, Janusz Cianciara, Andrzej Cieśla, Jacek Gąsiorowski, Andrzej Gietka, Ewa Gliwińska, Andrzej Gładysz, Zbigniew Gonciarz, Waldemar Halota, Małgorzata Inglot, Urszula Janas-Skulina, Ewa Janczewska-Kazek, Jolanta Jaskowska, Krzysztof Jurczyk, Jacek Juszczyk, Brygida Knysz, Wiesław Kryczka, Jan Kuydowicz, Anna Lakomy, Beata Logiewa-Bazger, Małgorzata Zejc-Bajsarowicz, Dorota Zarębska-Michaluk, Witold Wrodycki, Anna Łyczak, Tomasz Mach, Włodzimierz Mazur, Zofia Michalska, Roma Modrzewska, Khalil Nazzal, Paweł Pabjan, Anna Piekarska, Paweł Piszko

Med Sci Monit 2004; 10(1): 12-16 :: ID: 11832

Abstract

Open-label, multicenter extended availability program with peginterferon alfa-2a used in combination with ribavirin in patients with CHC in Poland was analysed. Finally, 572 patients were enrolled. The interim analysis of safety and tolerability was performed in 190 patients whose data were available after 72 weeks of observation. Mean hemoglobin level was 14.8 g/dl and decreased to week 24, then remain stable until the end of therapy and returned to the baseline value. Lekocytes level in week 2 decreased, reach a plateau in week 8 and return to baseline values at end observation. Similar phenomenon was observed with neutrophils. Platelet count during the treatment fell gradually in week 8 and remained stable. Reported adverse events requiring PEGASYS® or COPEGUS
® dose reduction were also analyzed. The most frequent adverse effect leading to the reduction of peginterferon alfa-2a dose was reduction. It was noted in 16 patients out of 18, who had the doses reduced because of adverse effects. Only in 5 patients, the dose was reduced because of depression or anxiety. Combined therapy was generally well-tolerated, preliminary analysis data confirms similar tolerability profile to that observed in phase III clinical trials.

Keywords: combination therapy with pegylated interferon alfa-2a and ribavirin, safety and tolerability, chronic hepatitis C

Add Comment 0 Comments

Editorial

01 March 2024 : Editorial  

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia

Dinah V. Parums

DOI: 10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

In Press

18 Mar 2024 : Clinical Research  

Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative Study

Med Sci Monit In Press; DOI: 10.12659/MSM.944136  

0:00

21 Feb 2024 : Clinical Research  

Potential Value of HSP90α in Prognosis of Triple-Negative Breast Cancer

Med Sci Monit In Press; DOI: 10.12659/MSM.943049  

22 Feb 2024 : Review article  

Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943168  

23 Feb 2024 : Clinical Research  

A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943732  

Most Viewed Current Articles

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750